Skip to main content
. 2019 Jul 30;10(46):4761–4775. doi: 10.18632/oncotarget.27109

Figure 2. KRAS expression is reduced significantly in KPC-1 pancreatic cancer cells and CT26 colorectal cancer cells.

Figure 2

(A) RT-PCR demonstrates decreased KRAS RNA expression in pancreatic (left side graph) and colorectal (right side graph) cancer cells treated with KRAS-siRNA NPs (KRAS NP), as compared to untreated cells (Control) or cells treated with scramble siRNA NP (SC NP). (B) CT26 colorectal cancer demonstrated decreased KRAS and phospho-ERK (pERK) expression after 24 hour treatment with KRAS NP treatment. ****=p < 0.0001, **=p < 0.01, 95% confidence intervals shown.